Preclinical | Phase 1 | Phase 2 | Phase 3/4 | Marketed | |
---|---|---|---|---|---|
Cardiovascular disease |
SP-8257 Stroke, Atherosclerosis |
Otaplimastat (SP-8203) Acute ischemic stroke |
CandeAmlo¢ç Hypertensive disease |
||
SP-8416 Heart failure |
CandeAmlo plus¢â Hypertensive disease |
EzeRosu¢ç Hyperlipidemia |
|||
OTAPLIMASTAT ALS Additional Indication |
|||||
Bone related disease |
Hyaltop¢ç Osteoarthritis |
Hyalflex¢ç Osteoarthritis |
|||
Medical Device |
MEDIFLEX Anti-adhesive |
Medicurtain¢ç Anti-adhesive |
|||
Infectious disease |
Pyramax¢ç tablets COVID-19 Drug repurposing |
Pyramax¢ç tablets Malaria WHO-MMV |
|||
Pyramax¢ç granules Malaria WHO-MMV |